$10 million pledge for international collaboration on vaccine research

As members of CEPI, New Zealand directly benefits from global achievements in vaccine research and development and manufacturing capability.   

CEPI’s 5-year plan includes:

• being able to develop vaccines for any future pandemic within 100 days of the viral sequence being identified
• developing pan-coronavirus vaccines and therapeutics that would apply across COVID-19 variants and other coronaviruses
• establish networks of global vaccine scientific and manufacturing capacity that can be rapidly utilised in any future pandemic.

CEPI are partners in the COVAX Facility, which plays a vital role in ensuring equitable access to COVID-19 vaccines for all nations in the world. Aotearoa New Zealand also provides active support to COVAX itself, contributing more than $26 million to date.

Shot in the arm for global vaccine development(external link) — Beehive.govt.nz